Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

The potent oral inhibitor of BCL2, venetoclax (VEN), used to treat adults with chronic lymphocytic leukaemia, has been approved in US for the treatment of naïve patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy and recently in Europe, too. However, the drug has been used fo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lucia Gozzo, Calogero Vetro, Serena Brancati, Laura Longo, Daniela Cristina Vitale, Giovanni Luca Romano, Elisa Mauro, Paolo Fabio Fiumara, Cinzia Maugeri, Marina Silvia Parisi, Ilaria Dulcamare, Bruno Garibaldi, Andrea Duminuco, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Filippo Drago
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
venetoclax
acute myeloid leukemia
off-label
effectiveness
adverse event
Therapeutics. Pharmacology
RM1-950
Accès en ligne:https://doaj.org/article/2ff780c252104344b836dc38e573699f
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/2ff780c252104344b836dc38e573699f

Documents similaires